Biostax (BTAX) 10-K 10 Apr 23 2022 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Mar. 31, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-54933
Entity Registrant Name	IMMUNE THERAPEUTICS, INC.
Entity Central Index Key	0001559356
Entity Tax Identification Number	59-3226705
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	2431 Aloma Ave.
Entity Address, Address Line Two	Suite 124
Entity Address, City or Town	Winter Park
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32792
City Area Code	888
Local Phone Number	613-8802
Title of 12(b) Security	Common Stock
Trading Symbol	IMUN
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 7.6
Entity Common Stock, Shares Outstanding		83,295,857
Documents Incorporated by Reference [Text Block]	None.
ICFR Auditor Attestation Flag	false
Auditor Firm ID	76
Auditor Name	Turner, Stone & Company, L.L.P
Auditor Location	Dallas, Texas

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current Assets:
Cash	$ 150,491	$ 493,885
Equity securities at fair value		2,645,000
Total current assets	150,491	3,138,885
Intangible Assets:
Patents and licenses	762,500
Deposits	50,728
Total Assets	963,719	3,138,885
Current Liabilities:
Accounts payable	1,300,366	2,184,848
Accrued payroll	336,002	3,421,176
Notes payable, net of debt discount	696,478	3,070,208
Due to related parties	394,736	891,420
Undocumented investor advances		715,631
Accrued interest	64,455	564,300
Accrued liabilities	136,057	239,558
License fees payable	549,079
Total current liabilities	3,477,173	11,087,141
Total Liabilities	3,477,173	11,087,141
Stockholders’ Deficit:
Common stock – par value $0.0001; 750,000,000 and 750,000,000 shares authorized, respectively; 83,045,857 and 483,714 shares issued and outstanding respectively	8,305	49
Additional paid in capital	380,436,432	371,473,810
Stock issuances due	10,303	10,303
Accumulated deficit	(382,968,494)	(379,432,418)
Total stockholders’ deficit	(2,513,454)	(7,948,256)
Total Liabilities and Stockholders’ Deficit	$ 963,719	$ 3,138,885

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	83,045,857	483,714
Common stock, shares outstanding	83,045,857	483,714

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenues, net
Cost of products sold
Gross profit
Operating expenses:
Selling, general and administrative	1,149,257	585,502
Research and development expense	14,236	152,667
Total operating expenses	1,163,493	738,169
Loss from operations	(1,163,493)	(738,169)
Other income (expense):
Gain on issuance of Forte license	3,165,151
Interest expense	(120,403)	(210,919)
Receipt of common shares		5,761,500
Change in market value of common shares	(2,645,000)	(3,116,500)
(Loss) gain on settlement of obligations and conversion of debt	(1,166,418)	711,892
Gain on derivative liability valuation		1,178,230
Charge from warrant modification and debt settlement	(1,605,913)
Total other income (expense)	(2,372,583)	4,324,203
Net (loss) income	$ (3,536,076)	$ 3,586,034
Basic earnings (loss) per share attributed to common stockholders	$ (0.10)	$ 7.43
Diluted earnings (loss) per share attributed to common stockholders	$ (0.10)	$ 0.38
Basic weighted average number of shares outstanding	36,290,359	482,826
Diluted weighted average number of shares outstanding	36,290,359	9,394,164

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock to be Issued [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2020	$ 48	$ 371,341,120	$ 10,303	$ (383,018,452)	$ (11,666,981)
Balance, shares at Dec. 31, 2020	476,504
Issuance of common stock upon conversion of notes	$ 1	56,479			56,480
Issuance of common stock upon conversion of notes, shares	5,402
Extinguishment of derivative liability upon conversion of debt		76,211			76,211
Effect of fractional shares upon reverse stock split
Effect of fractional shares upon reverse stock split, shares	1,808
Net Income (Loss)				3,586,034	3,586,034
Balance at Dec. 31, 2021	$ 49	371,473,810	10,303	(379,432,418)	(7,948,256)
Balance, shares at Dec. 31, 2021	483,714
Issuance of common stock upon conversion of notes	$ 6,413	6,276,755			6,283,168
Issuance of common stock upon conversion of notes, shares	64,125,963
Net Income (Loss)				(3,536,076)	(3,536,076)
Issuance of common stock upon exercise of warrants	$ 1,808	721,516			723,324
Issuance of common stock upon exercise of warrants, shares	18,086,680
Charge resulting from warrant modification		1,605,913			1,605,913
Issuance of common stock for services	$ 10	95,963			95,973
Issuance of common stock for services, shares	99,500
Issuance of common stock for intangible assets	$ 25	262,475			262,500
Issuance of common stock for intangible assets, shares	250,000
Balance at Dec. 31, 2022	$ 8,305	$ 380,436,432	$ 10,303	$ (382,968,494)	$ (2,513,454)
Balance, shares at Dec. 31, 2022	83,045,857

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income	$ (3,536,076)	$ 3,586,034
Adjustments to reconcile net loss to net cash flows used in operating activities:
Gain on issuance of Forte license agreement	(3,165,151)
Gain recognized upon receipt of equity securities		(5,761,500)
Loss on impairment on investment in common stock	2,645,000	3,116,500
Loss (gain) on settlement of obligations	1,166,418	(711,892)
Change in value of derivative liability		(1,178,230)
Amortization of debt discount		34,790
Loss from warrant modification	1,605,913
Changes in operating assets and liabilities:
Deposits	(50,728)	200
Accounts payable	388,539	103,752
Accrued payroll	4,620	24,000
Accrued interest	130,229	176,131
Accrued liabilities	(75,321)	18,498
Due to related parties	304,736	360,000
Net cash used in operating activities	(581,821)	(231,717)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of intangible assets	(500,000)
Net cash used in investing activities	(500,000)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from undocumented investor advances	6,369	715,631
Proceeds from related parties	417,058
Proceeds from issuance of notes	315,000
Net cash provided by financing activities	738,427	715,631
(Decrease) increase in cash	(343,394)	483,914
Cash and cash equivalents, beginning of year	493,885	9,971
Cash and cash equivalents, end of year	150,491	493,885
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Reclassification of accrued interest to notes payable	7,006,492	243,568
Conversion of notes and accrued interest to common stock	95,973	56,480
Stock issued for intangible assets	$ 262,500

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Company Overview Immune Therapeutics Inc. (the “Company” or “IMUN”) is a Florida Public Company trading on the OTC-Pink. The Company has been inactive for the last year due to a lack of funding, and with the Company’s current structure, it is impossible to move forward until a restructuring of the Company is completed. Going Concern As of December 31, 2022, the Company had $ 150,491 3,326,682 2,513,454 3,536,076 2,645,000 Historically the Company has relied on the funding of operations through private equity financings and management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its current or future product candidates as they become available and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources. Working capital at December 31, 2022 is not sufficient to meet the cash requirements to fund planned operations through the next twelve months without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. Management is developing as a strategy to re-capitalize the Company and position it for future growth. Key steps to this process include: ● Improve the condition of the balance sheet via license arrangements and capital infusions ● Identify and acquire late-stage assets for commercialization ● Build out operational infrastructure to generate revenue opportunities to grow shareholder value. There can be no guaranties that the Company will be successful in securing adequate capital to continue operations and in identifying and acquiring assets for future development. If the Company is unable to secure new working capital, other alternatives strategies will be required. Historically, the Company has been able to acquire and develop assets, spin them out and retain both an equity stake and royalties and milestone payments. In so doing, the Company has acted as an incubator for late-stage drug development. Management believes that this strategy can continue to be successful. At this time, the Company is reviewing several opportunities which it may pursue as soon as funding is available. At present no definitive actions have been taken. There can be no guaranties that the Company will be successful in: ● Executing its restructuring plan ● Securing adequate capital to continue operations. ● Identifying and acquiring assets for future development. Company History Immune Therapeutics, Inc. (“the Company”, “Immune”) was initially incorporated in Florida on December 2, 1993, as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2014, changing our name to Immune Therapeutics, Inc. On February 28, 2023, we received a written consent from a majority of our outstanding shareholders to change the name of our Company to “Biostax Corp.” We plan to file our name change amendment with the Secretary of State of Florida at least twenty calendar days after the filing of a definitive information statement on Schedule 14C, mailing of the information statement to shareholders on record as of the date of the filing of the definitive information statement, and after the Financial Industry Regulatory Authority, Inc. processes our name change. In December 2013, the Company formed a subsidiary, Cytocom Inc. (“ Cytocom Intellectual Property – Licensing” Stock Agreement 4,000,000 Intellectual Property – Licensing” 15.57% In the third quarter of 2021, Cytocom announced the completion of its merger with Cleveland BioLabs, Inc. (“ CBLI 1,150,000 The consolidated financial statements of the Company include the following inactive subsidiaries: (1) TNI BioTech, Ltd., a BVI company in Tortola, British Virgin Islands incorporated in October 2012 which was set up to market and sell Naltrexone outside the United States, (2) TNI BioTech, LTD, United Kingdom incorporated in August 2013 which was set up as a micro, small or medium-sized enterprise to be able to sell administrative and financial assistance programs offered by European Medicines Agency, (3) Airmed Biopharma Limited, Dublin Ireland incorporated in March 2014 which was set up to qualify for tax incentives for Irish holding/headquartered companies to benefit from the network of double tax treaties that reduce withholding taxes and (4) Airmed Holdings Limited an Irish company domiciled in Bermuda incorporated in March 2014 set up to manage international distribution.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (“GAAP”) and the Company’s discussion and analysis of its financial condition and operating results require the Company’s management to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results. Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $ 250,000 Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making. Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments” Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of the Company’s investment in the common stock of Statera BioPharma (“STAB”) is measured based on the quoted per share price as reported on NASDAQ and is a level 1 asset. The carrying value of notes payable approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes. Derivative Financial Instruments FASB ASC 815, Fair Value Measurements requires bifurcation of certain embedded derivative instruments in certain debt or equity instruments, and measurement at their fair value for accounting purposes. A holder redemption feature embedded in the Company’s note payable requires bifurcation from its host instrument and is accounted for as a freestanding derivative. The Company held no derivative financial instruments at December 31, 2022. Research and Development Costs Research and development costs are charged to expense as incurred and are comprised of fees paid to consultants and patent related costs. Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. As of December 31, 2022 and 2021, and at the date of adoption, the Company did not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2022 and 2021, the Company has not accrued any interest or penalties related to uncertain tax positions. Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors based on estimated fair values equaling either the market value of the shares issued, or the value of consideration received, whichever is more readily determinable. Generally, the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 718, “ Compensation – Stock Compensation Net Income per Share Basic net income per share is calculated by dividing the net income attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net income (loss) per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net income (loss) per share calculation, shares to be issued pursuant to convertible debt and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net income (loss) per share in 2022 because their effect would be anti-dilutive. A total of 38,495 15,218,668 The Company’s potentially dilutive securities which include primarily warrants, have been included in the computation of diluted net income per share for the twelve-month periods ended December 31, 2022 and 2021. A reconciliation of the weighted average shares outstanding used in basic and diluted earnings per share computation is as follows: Schedule of Basic and Dilute Earnings per Share Net Income Weighted Per Share Basic EPS (Loss) available to common stockholders $ (3,536,076 ) 36,260,359 $ (0.10 ) Diluted EPS Effect of warrants and notes payable convertible into common stock $ (3,536,076 ) 36,260,359 $ (0.10 ) Recent Accounting Standards During the year ended December 31, 2022, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Investment in Common Stock

Investment in Common Stock	12 Months Ended
	Dec. 31, 2022
Investment In Common Stock
Investment in Common Stock	Note 3. Investment in Common Stock In 2021, Cytocom, Inc., a former subsidiary of the Company (“Cytocom”), announced the completion of its merger with Cleveland BioLabs, Inc. (“CBLI”) which resulted in the Company’s receipt of 1,150,000 The Company evaluated the carrying value of the STAB common shares during the second quarter of 2022 and determined that an impairment loss of $ 362,250 2,645,000

Notes payable

Notes payable	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Notes payable	4. Notes payable As of December 31, 2022, the Company had $ 696,478 315,000 zero Notes Payable at December 31, 2022 and 2021: Schedule of Notes Payable 2022 2021 December 31, 2022 2021 Promissory notes issued between December 2014 and January 2015. Lender earns interest at 10%. Notes were to be repaid in 36 monthly instalments of principal and interest commencing no later than October 15, 2015. $ - $ 70,000 Promissory notes issued between December 2014 and January 2015. Lender earns interest at 10 36 $ - $ 70,000 Promissory notes issued between May 2015 and June 2016 and matured between February 2017 and November 2018 2 % and 10 %. $ - 149,500 Promissory notes were issued in 2016. The notes accrue interest at 2 November 2017 and December 2017 $ - 606,500 Promissory notes were issued in 2017 accrue interest at 2 January 2018 and September 2018 $ - 205,000 Promissory notes were issued in 2017 accrue interest at 2 May 2018 $ - 150,000 Promissory notes were issued in 2017 accrue interest at 2 August 2018 and September 2018 $ - 116,800 Promissory notes were issued in 2017 accrue interest at 2 $ - 105,500 Promissory notes were issued in the 2018 accrue interest at 2 May 2018 and January 2019 $ - 47,975 Promissory notes were issued in 2018 accrue interest at 2 1,000 5,000 5 $ - 65,000 Promissory notes were issued in 2018. The notes accrue interest at 2 August 2019 and January 2019 60,000 500,000 0.05 $ - 118,000 Promissory notes were issued in 2018. The notes accrue interest at 2 January 2019 and November 2019 200 39,500 5 40 $ - 323,855 Promissory note was issued to a related party in the first quarter of 2019. The note accrues interest at 2 July 2019 4,600 5 $ - 23,000 Promissory note was issued in the first quarter of 2019. The note accrues interest at 6 February 2020 $ 231,478 231,478 Promissory note was issued in the second quarter of 2019 accrues interest at 2 July 2019 10,000 5 $ - 10,000 Promissory note issued in 2019 for the settlement of debt in the same amount and matured in 2021. Lender earns interest at 15 November 2022 $ 150,000 150,000 Promissory notes issued in the first quarter of 2021 in connection with a Note Purchase Agreement with a previous note holder. The new notes reflect all principal, interest and penalties associated with the original instrument. These notes accrue interest at 5 7 348,800 - 697,600 Promissory note issued in 2022 and matures in 2023. Lender earns interest at 6 0.05 65,000 - Promissory note issued in 2022 and matures in 2023. Lender earns interest at 6 0.05 200,000 - Promissory note issued in 2022 and matures in 2023. Lender earns interest at 7.75 $ 50,000 - Total $ 696,478 $ 3,070,208 As of December 31, 2022 and 2021, the Company had accrued $ 64,455 564,300 Gain on Settlement of Debt During the year ended December 31, 2022, the Company recognized a non-cash loss of $ 1,166,418 711,892 In 2020 the Company and Cytocom entered into an agreement for the Company to sublicense LDN and MENK for emerging markets to Cytocom. Pursuant to the agreement, effective September 30, 2020 the Company assigned certain notes payable aggregating principal amount of $ 2,728,731 495,409

Common Stock and Common Stock W

Common Stock and Common Stock Warrants	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Common Stock and Common Stock Warrants	5. Common Stock and Common Stock Warrants Each holder of common stock is entitled to vote on all shareholder matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. As of December 31, 2022, and 2021, the Company was authorized to issue 750,000,000 750,000,000 0.0001 83,045,857 483,714 Common Stock Warrants The Company did not issue or modify any warrants in the twelve-month period ended December 31, 2022. When the Company sells its stock to stockholders for cash, it periodically issues common stock warrants to the investors at prices agreed at the date of the original sale. The Company incurs a cost for the rights attached to the warrants, which is calculated using the Black-Scholes Model and is reported in the Statements of Operations in the period of issuance. A summary of outstanding warrants as of December 31, 2022 follows: Schedule of Outstanding Common Stock Warrants Expiration Date Number of Exercise Price Remaining First Quarter 2023 4,000 $ 30 40 .25 Second Quarter 2023 1,000 200 .50 Third Quarter 2023 1,500 100 .75 Third Quarter 2028 3,000 70 5.75 Second Quarter 2032 28,995 10 70 9.50 38,495 $ 10 200 Following is a summary of outstanding stock warrants activity for the twelve months ended December 31, 2022 and 2021: Schedule of Stock Outstanding Warrants Activity Number of Exercise Weighted Warrants as of December 31, 2020 20,081,035 $ 0.05 200 $ 4.22 Issued - - - Expired and forfeited (23,873 ) 14 200 144,78 Exercised - - - Warrants as of December 31, 2021 20,057,162 2 290 5.21 Issued - - - Expired and forfeited (2,293,667 ) 0.05 290 205.25 Exercised (17,725,000 ) 0.05 0.05 Warrants as of December 31, 2022 38,495 $ 10 200 $ 59.42

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes There was no 92,490,000 Approximately $ 64,629,000 2033 27,861,000 will be limited to 80% of taxable income but will not expire The tax effects of temporary differences which give rise to deferred tax assets (liabilities) are summarized as follows: Deferred tax assets: Schedule of Deferred Tax Assets 2022 2021 Net operating losses $ 19,423,000 $ 23,281,000 Amortization, depreciation, and impairment - - Temporary differences 893,000 21,000 Total deferred tax assets 18,530,000 23,302,000 Valuation allowance (18,530,000 ) (23,302,000 ) Total deferred tax assets, net $ - $ - In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the realization of future taxable income during the periods in which those temporary differences become deductible. Deferred tax assets consist primarily of the tax effect of NOL carry-forwards. The Company has provided a full valuation allowance on the deferred tax assets because of the uncertainty regarding realizability. Schedule of Income Taxes Net Operating Loss For the year ended December 31, 2022 2021 Statutory federal tax rate 21.00 % 21.00 % Permanent differences (17.2 )% 11.4 % Temporary differences (25.3 )% 1,142.3 % Valuation allowance 21.5 % (1,174.7 )% Effective tax rate 0.0 % 0.0 % Provision for income taxes - - The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statement of operations. As of December 31, 2022, and 2021, the Company had no unrecognized tax benefits. There were no changes in the Company’s unrecognized tax benefits during the years ended December 31, 2022 and 2021. The Company did not recognize any interest or penalties during fiscal 2022 or 2021 related to unrecognized tax benefits.

Licenses and Supply Agreements

Licenses and Supply Agreements	12 Months Ended
	Dec. 31, 2022
Licenses And Supply Agreements
Licenses and Supply Agreements	8. Licenses and Supply Agreements Forte Animal Health, Inc. On July 8, 2021, the Company amended the license agreement (the “Amended License Agreement”) with Forte Animal Health Inc. (“Forte”), a related party, dated February 27, 2020. Under the Amended License Agreement, the Company granted Forte an exclusive license to develop and commercialize pharmaceutical products consisting of Lodonal and MENK for use in veterinary applications for all indications world-wide. Milestone payments and royalties are defined in the agreement based on development and royalties are based on sales during the license period. The initial license fee included the assignment of certain Company defaulted notes and other vendor and employee obligations. During the second quarter of 2022, these debtors associated with the assigned obligations completed the assignment of $ 1,775,275 264,790 1,125,086 In connection with the amended license agreement, Forte issued 2,235,000 15 Forte has agreed to make payments to the Company in connection with this agreement as follows: ● Initial License Fee, upon the assignment of certain Company Notes Payable. ● Development Milestone Payments upon the occurrence of the identified events, one-time, non-creditable, non-refundable milestone payments of $ 100,000 ● Commercial Milestone Payments upon reaching the mutually agreed aggregate net sales. Forte will pay one-time, non-creditable, non-refundable milestone payments to be negotiated and addressed in a separate Amendment later. ● Royalties during the royalty term (generally 15 Schedule of Royalty Rate Annual Sales of Royalty Qualifying Licensed Products Royalty Rate <$500,000,000 2 % 500,000,000 to < $1,000,000,000 4 % > $1,000,000,000) 6 % Cytocom On May 13, 2020, the Company and Cytocom entered into an Amendment to The Second Amendment to The License Agreement (“Third Amendment”) that was effective December 31, 2018. The sublicense provides Cytocom with the Company’s previously licensed rights for LDN and MENK in Emerging Markets. Original terms for consideration for the sublicense were not finalized until August 12, 2020, at which time Cytocom and the Company signed a letter agreement in which Cytocom agreed to assume a combination of defaulted notes plus certain other liabilities. Such terms were amended, and the Company agreed to transfer all the rights, title, and interest to Cytocom in technology licensed from Penn State Research Foundation (“PSU”) in exchange for Cytocom assuming all past due and future obligations under the PSU license. While the Company formalized the agreement to assign all outstanding liabilities due to PSU, a vendor of the Company, PSU did not consent to the assignment of the payables to Cytocom. As of December 31, 2021, the Company had no outstanding accounts payable balances due to Penn State University. On July 20, 2021, Cytocom and the Company agreed to modify the terms of the original sublicense. The renegotiated terms are presented below. The assignment of the Notes and associated accrued interest and penalties in default was fully executed in the third quarter of 2020 with the transfer of the notes upon the creditors’ signoff. The Company recognized a gain upon the assignment of these notes in the third quarter of 2020. Cytocom has not completed the assumption of the remaining liabilities. Cytocom and the Company are actively engaged in negotiations to modify the terms of the original sublicense. The Company expects the additional amendment to be executed by both parties in the quarter ending June 30, 2023. Consideration for License to Cytocom as of December 31, 2022 Schedule of Consideration Consideration / Assumption of: Notes and associated accrued interest in default $ 3,302,209 Accounts payable and accruals 230,000 Past Due Employee Obligations 1,110,567 Total anticipated Consideration $ 4,642,776 Recognized through December 31, 2020 (3,302,209 ) To Be Recognized upon Execution $ 1,340,567 As of December 31, 2022, the Notes transaction has not been fully executed. The Notes in default have been assigned and the transfer signed off by the creditors, but Cytocom still has not completed the assumption of the agreed upon obligations. Until the transaction is completed Cytocom (Statera) does not have clear title and interest to the Immune technology. In March 2023, the Company and Cytocom negotiated an amendment to the licensing agreement (“Third License Amendment”) which has been submitted to the board of directors of Cytocom for approval. The Third License Amendment: ● Restates the licensing arrangement between the Company and Cytocom and grants the Company manufacturing, distribution and marketing rights for LDN and MENK, in humans for all indications except Crohn’s Disease (worldwide), and animals (US only). ● Grants the Company the right grant sublicenses to third parties for the manufacturing, distribution and marketing of these products. ● Updates the royalty rates as follows: Annual Sales of Royalty Qualifying Licensed Products Royalty Rate <$500,000,000 2 % 500,000,000 to < $1,000,000,000 4 % > $1,000,000,000) 6 % The Company anticipates the Third License Amendment to be approved in April 2023. TaiwanJ Pharmaceuticals Co. Ltd. On September 30, 2022, the Company entered into an Intellectual Property License Agreement (the “ Agreement TaiwanJ Products The Company also received a non-exclusive worldwide right to make, manufacture, and receive technical manufacturing assistance from TaiwanJ for the creation of the Products. The only territories excluded from the scope of the Agreement are any countries or territories in Asia, and any countries or territories barred or sanctioned by the United States government. We did not have any relationship with TaiwanJ prior to entering into the Agreement. The term of this Agreement is to be perpetual, but termination of the Agreement may occur upon (i) the Company providing sixty (60) days prior written notice to TaiwanJ of termination, (ii) termination of the agreement for a material breach of the agreement, and failure to cure that breach within ninety (90) days after receiving notice of such breach, (iii) the dissolution of the Company, or (iv) upon bankruptcy of either party, upon receiving sixty (60) days’ notice by Registered Mail. The Company may grant sublicenses under the Agreement. Upon the granting of any such sublicense, the Company will pay TaiwanJ royalties based on the stage of development of the Products. The Company will pay a royalty of 30 10 5 NDA Pursuant to the terms of the license in the Agreement, the Company shall adhere to a plan of development and attain certain milestones. As part of the Development Plan, the Company shall (i) use commercially reasonable efforts and cause its sublicenses to use commercially reasonable efforts to develop licensed Products, (ii) begin commercial sales of the Products in a country no less than eight (8) months after the first registration of the Products in that same country, and (iii) following commercialization, the Company must keep the Products reasonably available to the public. In consideration for the license, the Company will provide (i) a non-refundable cash payment of $500,000 within ninety (90) days of September 30, 2022, (ii) a non-refundable cash payment of $500,000 at the earliest of either the National Agency for Food and Drug Administration and Control (“ NAFDAC FDA The Company will be required to pay one-time payments and issuances of equity for the achievement of each of four milestones in the commercialization and development of the Products. In addition to the milestone payments, if there is any year that the Company is not required to pay a Milestone Payment, the Company will pay a royalty percentage payment based on the total net sales due within sixty (60) days after the end of each calendar quarter (the “ Royalty Payment If the Company fails to make any of the above-described payments upon their designated due date, the payment amount will bear the lower of (i) 1.5% interest per month or (ii) the maximum rate allowed by law, to be compounded quarterly. The interest will accrue beginning on the first day after the payment is due TaiwanJ will maintain, protect, and defend all patent-related intellectual property and the Company will reimburse TaiwanJ for any expenses related to intellectual property patent payments that exclusively benefit the Company. If either the Company or TaiwanJ becomes aware of any possible or actual infringement of any patent rights, then each party will notify the other, and provide it with details of such an infringement. Both the Company and TaiwanJ are limited in liability to the total amounts paid under this Agreement for any damages arising from negligence, strict liability, or any other equitable theory. Further, both the Company and TaiwanJ agree to indemnify and hold harmless each other, and their respective agents, for any claims or costs arising from this Agreement or any sublicenses for any cause of action relating to any product, process, service made, used, or sold pursuant to this Agreement. On January 19, 2023, the Company’s board of directors voted to issue an additional 250,000 500,000

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Our principal commitments consist mostly of obligations under the loans described above, the operating leases described under Item 2 “Properties” and obligations disclosed under various licensing agreements. We do not have any purchase obligations with any suppliers.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	10. Related Party Transactions On November 1, 2022 we entered into a consulting agreement with Kelly Wilson, our Interim Chief Executive Officer, Interim President and Chief Operating Officer. Pursuant to the terms of the consulting agreement, we agreed to pay Ms. Wilson a monthly fee of $ 21,000 2,800 (a) 25% below any current offering price (or the most recent offering price if the Company is not engaged in the offering) or (b) 50% below the Company’s current common stock value as determined by the average of the previous 30 days’ closing market prices On November 1, 2022 we entered into a consulting agreement with Glen Farmer, our Chief Financial Officer. Pursuant to the terms of the consulting agreement, we agreed to pay Mr. Farmer a monthly fee of $ 10,500 2,800 (a) 25% below any current offering price (or the most recent offering price if the Company is not engaged in the offering) or (b) 50% below the Company’s current common stock value as determined by the average of the previous 30 days’ closing market prices On April 29, 2020, we entered into an employment agreement with Kevin Phelps, our former Chief Executive Officer and Chief Financial Officer, setting forth the terms of Mr. Phelps’s employment. Pursuant to the terms of the employment agreement, we agreed to pay Mr. Phelps an annual base salary of $ 240,000 Mr. Phelps was also eligible to receive a salary increase of 20% for his second year of employment and a salary increase of 15% for his third year of employment. Mr. Phelps also had the opportunity to receive a discretionary bonus of up to 33% based on the achieved milestones and goals On July 19, 2022, we entered into a separation agreement and release with Mr. Phelps providing for the separation of his employment effective as of July 18, 2022. Under the separation agreement, we agreed, subject to Mr. Phelps’s compliance with each and every provision of the separation agreement, to pay Mr. Phelps a severance payment of three convertible promissory notes, that in the aggregate, have a principal amount of $ 400,000 Two of the notes are for a principal amount of $ 100,000 The third note is for the principal amount of $ 200,000 July 19, 2023 6.00% 0.05 200,000 2,500,000 100,000 On July 5, 2022, the Company’s board of directors approved the issuance of a $ 200,000 0.05 Under a Settlement Agreement and Release of Claims, dated July 1, 2022, among Kelly Wilson, Robert Wilson, and Noreen Griffin (collectively, the “Employees”), Murphy Advisors, and the Company (the “July 2022 Settlement Agreement”), the Company agreed to issue a convertible note in order to settle debts due to the Employees for past due wages and out-of-pocket reimbursable expenses. The Company owed $ 313,164 52,578 365,742 1,231,787 230,000 1,827,530 Pursuant to the July 2022 Settlement Agreement, the Company agreed to issue a 6 1,211,366 0.05 On July 25, 2022, Murphy Advisors converted the Murphy Note into 24,227,320 shares of common stock, of which Murphy Advisors received 15,604,818 shares, Pixelheads, Inc., of whose shares Mr. Wilson is the sole beneficial owner, received 3,695,358 shares, and Global Reverb Corporation, of whose shares Ms. Griffin is the sole beneficial owner, received the remaining 4,927,144 shares. All shares issued as a result of converting the Murphy Note are required to be restricted from transfer for 12 months following the date of issuance, then subject to a lock-up leak of 5% per quarter for three out of four quarters for the following 18 months On March 31, 2022, the Company entered into a Release of Claims and Settlement Agreement with Dr. Moore. The agreement provided for release of employment, breach of contract and related claims and settlement of aggregate accrued but unpaid compensation through March 31, 2022. Pursuant to the agreement, Dr. Moore released claims to a total of $ 230,250 15,000 60,000 120,000 95,250 230,250 6 135,000 4,605,000 Similarly, on March 31, 2022, the Company entered into a Release of Claims and Settlement Agreement with Dr. Selsky. The agreement provided for release of employment, breach of contract and related claims and settlement of aggregate accrued but unpaid compensation for services that were provided through March 31, 2022. Pursuant to the agreement, Dr. Selsky released claims for a total of $ 250,000 15,000 35,000 50,000 125,000 6 125,000 2,500,000 2,500,000 On March 24, 2023, the Company issued a $ 100,000 8

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events On January 10, 2023, the Majority Shareholders consented in writing to approve the Company’s conversion from a Florida corporation to a Nevada corporation (the “ Conversion 42,225,908 50.83 On February 28, 2023, the Majority Shareholders approved by written consent, in lieu of a special meeting, Articles of Amendment to change the name of the Company to “Biostax Corp.” On January 19, 2023, the Company issued 250,000 On March 24, 2023, the Company issued $ 150,000 100,000 mature in 90 days 8

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (“GAAP”) and the Company’s discussion and analysis of its financial condition and operating results require the Company’s management to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $ 250,000
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments” Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of the Company’s investment in the common stock of Statera BioPharma (“STAB”) is measured based on the quoted per share price as reported on NASDAQ and is a level 1 asset. The carrying value of notes payable approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.
Derivative Financial Instruments	Derivative Financial Instruments FASB ASC 815, Fair Value Measurements requires bifurcation of certain embedded derivative instruments in certain debt or equity instruments, and measurement at their fair value for accounting purposes. A holder redemption feature embedded in the Company’s note payable requires bifurcation from its host instrument and is accounted for as a freestanding derivative. The Company held no derivative financial instruments at December 31, 2022.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred and are comprised of fees paid to consultants and patent related costs.
Income Taxes	Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. As of December 31, 2022 and 2021, and at the date of adoption, the Company did not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2022 and 2021, the Company has not accrued any interest or penalties related to uncertain tax positions.
Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration	Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors based on estimated fair values equaling either the market value of the shares issued, or the value of consideration received, whichever is more readily determinable. Generally, the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 718, “ Compensation – Stock Compensation
Net Income per Share	Net Income per Share Basic net income per share is calculated by dividing the net income attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net income (loss) per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net income (loss) per share calculation, shares to be issued pursuant to convertible debt and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net income (loss) per share in 2022 because their effect would be anti-dilutive. A total of 38,495 15,218,668 The Company’s potentially dilutive securities which include primarily warrants, have been included in the computation of diluted net income per share for the twelve-month periods ended December 31, 2022 and 2021. A reconciliation of the weighted average shares outstanding used in basic and diluted earnings per share computation is as follows: Schedule of Basic and Dilute Earnings per Share Net Income Weighted Per Share Basic EPS (Loss) available to common stockholders $ (3,536,076 ) 36,260,359 $ (0.10 ) Diluted EPS Effect of warrants and notes payable convertible into common stock $ (3,536,076 ) 36,260,359 $ (0.10 )
Recent Accounting Standards	Recent Accounting Standards During the year ended December 31, 2022, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Basic and Dilute Earnings per Share	A reconciliation of the weighted average shares outstanding used in basic and diluted earnings per share computation is as follows: Schedule of Basic and Dilute Earnings per Share Net Income Weighted Per Share Basic EPS (Loss) available to common stockholders $ (3,536,076 ) 36,260,359 $ (0.10 ) Diluted EPS Effect of warrants and notes payable convertible into common stock $ (3,536,076 ) 36,260,359 $ (0.10 )

Notes payable (Tables)

Notes payable (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes Payable at December 31, 2022 and 2021: Schedule of Notes Payable 2022 2021 December 31, 2022 2021 Promissory notes issued between December 2014 and January 2015. Lender earns interest at 10%. Notes were to be repaid in 36 monthly instalments of principal and interest commencing no later than October 15, 2015. $ - $ 70,000 Promissory notes issued between December 2014 and January 2015. Lender earns interest at 10 36 $ - $ 70,000 Promissory notes issued between May 2015 and June 2016 and matured between February 2017 and November 2018 2 % and 10 %. $ - 149,500 Promissory notes were issued in 2016. The notes accrue interest at 2 November 2017 and December 2017 $ - 606,500 Promissory notes were issued in 2017 accrue interest at 2 January 2018 and September 2018 $ - 205,000 Promissory notes were issued in 2017 accrue interest at 2 May 2018 $ - 150,000 Promissory notes were issued in 2017 accrue interest at 2 August 2018 and September 2018 $ - 116,800 Promissory notes were issued in 2017 accrue interest at 2 $ - 105,500 Promissory notes were issued in the 2018 accrue interest at 2 May 2018 and January 2019 $ - 47,975 Promissory notes were issued in 2018 accrue interest at 2 1,000 5,000 5 $ - 65,000 Promissory notes were issued in 2018. The notes accrue interest at 2 August 2019 and January 2019 60,000 500,000 0.05 $ - 118,000 Promissory notes were issued in 2018. The notes accrue interest at 2 January 2019 and November 2019 200 39,500 5 40 $ - 323,855 Promissory note was issued to a related party in the first quarter of 2019. The note accrues interest at 2 July 2019 4,600 5 $ - 23,000 Promissory note was issued in the first quarter of 2019. The note accrues interest at 6 February 2020 $ 231,478 231,478 Promissory note was issued in the second quarter of 2019 accrues interest at 2 July 2019 10,000 5 $ - 10,000 Promissory note issued in 2019 for the settlement of debt in the same amount and matured in 2021. Lender earns interest at 15 November 2022 $ 150,000 150,000 Promissory notes issued in the first quarter of 2021 in connection with a Note Purchase Agreement with a previous note holder. The new notes reflect all principal, interest and penalties associated with the original instrument. These notes accrue interest at 5 7 348,800 - 697,600 Promissory note issued in 2022 and matures in 2023. Lender earns interest at 6 0.05 65,000 - Promissory note issued in 2022 and matures in 2023. Lender earns interest at 6 0.05 200,000 - Promissory note issued in 2022 and matures in 2023. Lender earns interest at 7.75 $ 50,000 - Total $ 696,478 $ 3,070,208

Common Stock and Common Stock_2

Common Stock and Common Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Outstanding Common Stock Warrants	A summary of outstanding warrants as of December 31, 2022 follows: Schedule of Outstanding Common Stock Warrants Expiration Date Number of Exercise Price Remaining First Quarter 2023 4,000 $ 30 40 .25 Second Quarter 2023 1,000 200 .50 Third Quarter 2023 1,500 100 .75 Third Quarter 2028 3,000 70 5.75 Second Quarter 2032 28,995 10 70 9.50 38,495 $ 10 200
Schedule of Stock Outstanding Warrants Activity	Following is a summary of outstanding stock warrants activity for the twelve months ended December 31, 2022 and 2021: Schedule of Stock Outstanding Warrants Activity Number of Exercise Weighted Warrants as of December 31, 2020 20,081,035 $ 0.05 200 $ 4.22 Issued - - - Expired and forfeited (23,873 ) 14 200 144,78 Exercised - - - Warrants as of December 31, 2021 20,057,162 2 290 5.21 Issued - - - Expired and forfeited (2,293,667 ) 0.05 290 205.25 Exercised (17,725,000 ) 0.05 0.05 Warrants as of December 31, 2022 38,495 $ 10 200 $ 59.42

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	Schedule of Deferred Tax Assets 2022 2021 Net operating losses $ 19,423,000 $ 23,281,000 Amortization, depreciation, and impairment - - Temporary differences 893,000 21,000 Total deferred tax assets 18,530,000 23,302,000 Valuation allowance (18,530,000 ) (23,302,000 ) Total deferred tax assets, net $ - $ -
Schedule of Income Taxes Net Operating Loss	Schedule of Income Taxes Net Operating Loss For the year ended December 31, 2022 2021 Statutory federal tax rate 21.00 % 21.00 % Permanent differences (17.2 )% 11.4 % Temporary differences (25.3 )% 1,142.3 % Valuation allowance 21.5 % (1,174.7 )% Effective tax rate 0.0 % 0.0 % Provision for income taxes - -

Licenses and Supply Agreements

Licenses and Supply Agreements (Tables)	12 Months Ended
	Dec. 31, 2022
Licenses And Supply Agreements
Schedule of Royalty Rate	Schedule of Royalty Rate Annual Sales of Royalty Qualifying Licensed Products Royalty Rate <$500,000,000 2 % 500,000,000 to < $1,000,000,000 4 % > $1,000,000,000) 6 % Annual Sales of Royalty Qualifying Licensed Products Royalty Rate <$500,000,000 2 % 500,000,000 to < $1,000,000,000 4 % > $1,000,000,000) 6 %
Schedule of Consideration	Consideration for License to Cytocom as of December 31, 2022 Schedule of Consideration Consideration / Assumption of: Notes and associated accrued interest in default $ 3,302,209 Accounts payable and accruals 230,000 Past Due Employee Obligations 1,110,567 Total anticipated Consideration $ 4,642,776 Recognized through December 31, 2020 (3,302,209 ) To Be Recognized upon Execution $ 1,340,567

Organization and Description _2

Organization and Description of Business (Details Narrative) - USD ($)		3 Months Ended	12 Months Ended
	Jun. 04, 2018	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash			$ 150,491
Working capital			3,326,682
Stockholders' deficit			2,513,454	$ 7,948,256	$ 11,666,981
Net loss			3,536,076
Nonoperating gains (Losses)			$ 2,645,000
Stock Agreement [Member] | Cytocom [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cancellation of debt	$ 4,000,000
Outstanding common stock, percentage	15.57%
Stock Agreement [Member] | Cleveland Bio Labs Inc [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued		$ 1,150,000

Schedule of Basic and Dilute Ea

Schedule of Basic and Dilute Earnings per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Basic EPS, income available to common stockholders	$ (3,536,076)
Basic EPS, weighted average common shares, basic	36,260,359
Basic earnings per share	$ (0.10)	$ 7.43
Diluted EPS, effect of warrants and notes payable convertible into common stock	$ (3,536,076)
Diluted EPS, weighted average common shares, diluted	36,260,359
Diluted earnings per share	$ (0.10)	$ 0.38

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	12 Months Ended
	Dec. 31, 2022 USD ($) shares
Accounting Policies [Abstract]
Cash at federal deposit | $	$ 250,000
Number of warrants	38,495
Number of anti-dilutive shares resulting from conversion	15,218,668

Investment in Common Stock (Det

Investment in Common Stock (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Impairment loss investment in common stock		$ 2,645,000	$ 3,116,500
Cleveland Bio Labs Inc [Member]
Stock issued during period, shares, acquisitions			1,150,000
Statera BioPharma, Inc. [Member]
Impairment loss investment in common stock	$ 362,250	$ 2,645,000

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	3 Months Ended		12 Months Ended				14 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2022	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2021
Short-Term Debt [Line Items]
Total			$ 696,478					$ 3,070,208
Notes Payable One [Member]
Short-Term Debt [Line Items]
Notes payable								70,000
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Notes payable								149,500
Notes Payable Two [Member] | Lenders [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date, description							February 2017 and November 2018
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Notes payable								606,500
Debt instrument, maturity date, description						November 2017 and December 2017
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Notes payable								205,000
Debt instrument, maturity date, description					January 2018 and September 2018
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Notes payable								150,000
Debt instrument, maturity date, description					May 2018
Notes Payable Six [Member]
Short-Term Debt [Line Items]
Notes payable								116,800
Debt instrument, maturity date, description					August 2018 and September 2018
Notes Payable Seven [Member]
Short-Term Debt [Line Items]
Notes payable								105,500
Notes Payable Eight [Member]
Short-Term Debt [Line Items]
Notes payable								47,975
Debt instrument, maturity date, description				May 2018 and January 2019
Notes Payable Nine [Member]
Short-Term Debt [Line Items]
Notes payable								65,000
Notes Payable Ten [Member]
Short-Term Debt [Line Items]
Notes payable								118,000
Debt instrument, maturity date, description				August 2019 and January 2019
Notes Payable Eleven [Member]
Short-Term Debt [Line Items]
Notes payable								323,855
Debt instrument, maturity date, description				January 2019 and November 2019
Notes Payable Twelve [Member]
Short-Term Debt [Line Items]
Notes payable								23,000
Debt instrument, maturity date, description		July 2019
Notes Payable Thirteen [Member]
Short-Term Debt [Line Items]
Notes payable			231,478					231,478
Debt instrument, maturity date, description		February 2020
Notes Payable Fourteen [Member]
Short-Term Debt [Line Items]
Notes payable								10,000
Debt instrument, maturity date, description	July 2019
Notes Payable Fifteen [Member]
Short-Term Debt [Line Items]
Notes payable			$ 150,000					150,000
Debt instrument, maturity date, description			November 2022
Notes Payable Seventeen [Member]
Short-Term Debt [Line Items]
Notes payable								697,600
Notes Payable Eighteen [Member]
Short-Term Debt [Line Items]
Notes payable			65,000
Notes Payable Nineteen [Member]
Short-Term Debt [Line Items]
Notes payable			200,000
Notes Payable Twenty [Member]
Short-Term Debt [Line Items]
Notes payable			$ 50,000

Schedule of Notes Payable (De_2

Schedule of Notes Payable (Details) (Parenthetical)	2 Months Ended	3 Months Ended		12 Months Ended				14 Months Ended
	Jan. 31, 2015 Integer	Jun. 30, 2019 shares	Mar. 31, 2019	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2018 $ / shares shares	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2016	Mar. 31, 2021 USD ($)	Dec. 31, 2019 $ / shares shares
Short-Term Debt [Line Items]
Percentage of interest rate per annum				6%
Class of Warrant or Right, Outstanding | shares				38,495
Debt Instrument, Face Amount | $				$ 200,000
Minimum [Member]
Short-Term Debt [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 10
Maximum [Member]
Short-Term Debt [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 200
Notes Payable One [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum	10%
Number of installments | Integer	36
Notes Payable Two [Member] | Lenders [Member]
Short-Term Debt [Line Items]
Debt Instrument, Maturity Date, Description								February 2017 and November 2018
Notes Payable Two [Member] | Lenders [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum								2%
Debt instrument interest rate penalty percentage								10%
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum							2%
Debt Instrument, Maturity Date, Description							November 2017 and December 2017
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum						2%
Debt Instrument, Maturity Date, Description						January 2018 and September 2018
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum						2%
Debt Instrument, Maturity Date, Description						May 2018
Notes Payable Six [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum						2%
Debt Instrument, Maturity Date, Description						August 2018 and September 2018
Notes Payable Seven [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum						2%
Notes Payable Eight [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum					2%
Debt Instrument, Maturity Date, Description					May 2018 and January 2019
Notes Payable Nine [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum					2%
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 5
Notes Payable Nine [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Class of Warrant or Right, Outstanding | shares					1,000
Notes Payable Nine [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Class of Warrant or Right, Outstanding | shares					5,000
Notes Payable Ten [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum					2%
Debt Instrument, Maturity Date, Description					August 2019 and January 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.05
Notes Payable Ten [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Class of Warrant or Right, Outstanding | shares					60,000
Notes Payable Ten [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Class of Warrant or Right, Outstanding | shares					500,000
Notes Payable Eleven [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum					2%
Debt Instrument, Maturity Date, Description					January 2019 and November 2019
Notes Payable Eleven [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Class of Warrant or Right, Outstanding | shares					200
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 5
Notes Payable Eleven [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Class of Warrant or Right, Outstanding | shares					39,500
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 40
Notes Payable Twelve [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum			2%
Debt Instrument, Maturity Date, Description			July 2019
Class of Warrant or Right, Outstanding | shares										4,600
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 5
Notes Payable Thirteen [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum			6%
Debt Instrument, Maturity Date, Description			February 2020
Notes Payable Fourteen [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum		2%
Debt Instrument, Maturity Date, Description		July 2019
Class of Warrant or Right, Outstanding | shares		10,000
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 5
Notes Payable Fifteen [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum				15%
Debt Instrument, Maturity Date, Description				November 2022
Notes Payable Seventeen [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum									5%
Debt instrument penalty percentage									7%
Notes Payable Seventeen [Member] | Note Purchase Agreement [Member]
Short-Term Debt [Line Items]
Debt Instrument, Face Amount | $									$ 348,800
Notes Payable Eighteen [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum				6%
Notes Payable Eighteen [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Debt conversion, price				$ 0.05
Notes Payable Nineteen [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum				6%
Notes Payable Nineteen [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Debt conversion, price				$ 0.05
Notes Payable Twenty [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum				7.75%

Notes payable (Details Narrativ

Notes payable (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Promissory notes payable to shareholders	$ 64,455	$ 564,300
Gain loss on settlement of obligations	1,166,418	(711,892)
Gain loss on settlement of obligations	(1,166,418)	711,892
Principal amount	200,000
Cytocom [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Principal amount			$ 2,728,731
Accurued interest			$ 495,409
Shareholders [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Notes payable	696,478
Promissory Notes [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Notes payable	$ 315,000	$ 0

Schedule of Outstanding Common

Schedule of Outstanding Common Stock Warrants (Details)	Dec. 31, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	38,495
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 10
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 200
First Quarter 2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	4,000
Remaining Life	3 months
First Quarter 2023 [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 30
Second Quarter 2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	1,000
Exercise price	$ 200
Remaining Life	6 months
Second Quarter 2023 [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 40
Third Quarter 2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	1,500
Exercise price	$ 100
Remaining Life	9 months
Third Quarter 2028 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	3,000
Exercise price	$ 70
Remaining Life	5 years 9 months
Second Quarter 2032 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	28,995
Remaining Life	9 years 6 months
Second Quarter 2032 [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 10
Second Quarter 2032 [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 70

Schedule of Stock Outstanding W

Schedule of Stock Outstanding Warrants Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Warrants, Beginning balance	20,057,162	20,081,035
Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price	$ 5.21	$ 4.22
Number of Shares Warrants, Issued
Exercise Price, Issued
Weighted Average Price, Issued
Number of Shares Warrants, Expired and forfeited	(2,293,667)	(23,873)
Weighted Average Price, Expired and forfeited	$ 205.25	$ 144.78
Number of Shares Warrants, Exercised	(17,725,000)
Exercise Price, Exercised	$ 0.05
Weighted Average Price, Exercised	$ 0.05
Number of Shares Warrants, Ending balance	38,495	20,057,162
Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price award non options outstanding weighted average price	$ 59.42	$ 5.21
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price, Beginning balance	2	0.05
Exercise Price, Expired and forfeited	0.05	14
Exercise Price, Ending balance	10	2
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price, Beginning balance	290	200
Exercise Price, Expired and forfeited	290	200
Exercise Price, Ending balance	$ 200	$ 290

Common Stock and Common Stock_3

Common Stock and Common Stock Warrants (Details Narrative) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Common stock, shares authorized	750,000,000	750,000,000
Common stock, par or stated value per share	$ 0.0001	$ 0.0001
Common stock, shares, outstanding	83,045,857	483,714

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Net operating losses	$ 19,423,000	$ 23,281,000
Amortization, depreciation, and impairment
Temporary differences	893,000	21,000
Total deferred tax assets	18,530,000	23,302,000
Valuation allowance	(18,530,000)	(23,302,000)
Total deferred tax assets, net

Schedule of Income Taxes Net Op

Schedule of Income Taxes Net Operating Loss (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Statutory federal tax rate	21%	21%
Permanent differences	(17.20%)	11.40%
Prior period adjustment	(25.30%)	1,142.30%
Valuation allowance	21.50%	(1174.70%)
Provision for income taxes	0%	0%
Provision for income taxes

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Expense (Benefit)	$ 0	$ 0
Operating loss Carryforwards	$ 92,490,000
Income tax examination description	2033
Operating loss carryforwards limitations on use	27,861,000 will be limited to 80% of taxable income but will not expire
Expire in Two Thousand Thirty Three [Member]
Operating loss Carryforwards	$ 64,629,000

Schedule of Royalty Rate (Detai

Schedule of Royalty Rate (Details)	Feb. 27, 2020
Less than 500,000,000 [Member]
Royalty Rate	2%
From 500,000,000 to less than 1,000,000,000 [Member]
Royalty Rate	4%
Greater than 1,000,000,000 [Member]
Royalty Rate	6%

Schedule of Consideration (Deta

Schedule of Consideration (Details) - Cytocom inc [Member]	12 Months Ended
	Dec. 31, 2022 USD ($)
Notes in Default	$ 3,302,209
Accounts payable and accruals	230,000
Past Due Employee Obligations	1,110,567
Total anticipated Consideration	4,642,776
Recognized through December 31, 2020	(3,302,209)
Total Consideration to be Recognized Upon Execution	$ 1,340,567

Licenses and Supply Agreement_2

Licenses and Supply Agreements (Details Narrative) - USD ($)			12 Months Ended
	Jan. 19, 2023	Feb. 27, 2020	Dec. 31, 2022	Mar. 31, 2023	Jun. 30, 2022	Dec. 31, 2021
Notes payable			$ 64,455			$ 564,300
Cash payment, description			In consideration for the license, the Company will provide (i) a non-refundable cash payment of $500,000 within ninety (90) days of September 30, 2022, (ii) a non-refundable cash payment of $500,000 at the earliest of either the National Agency for Food and Drug Administration and Control (“NAFDAC”) approval for JKB-122 in Africa for any indication, or the enrollment of the first patient in a Food and Drug Administration (“FDA”) trail for Crohn’s Disease, (iii) 250,000 shares of common stock of the Company within sixty (60) days of September 30, 2022, (iv) an annual payment of $100,000 each anniversary of the date of the agreement until the Company gains regulatory approval in Africa, (v) milestone payments (described below), and (vi) royalties on net sales. The 250,000 shares of common stock represent approximately 0.32% of the currently outstanding common stock of the Company.
Description for monthly interest for payment			the payment amount will bear the lower of (i) 1.5% interest per month or (ii) the maximum rate allowed by law, to be compounded quarterly. The interest will accrue beginning on the first day after the payment is due
Common Stock [Member]
Number of shares issued			18,086,680
Sublicense Occurs Before Completing a Clinical Trial [Member]
Royalty percentage			30%
Sublicense Occurs After Completing a Clinical Trial [Member]
Royalty percentage			10%
Sublicense Occurs After Any New Drug Application (NDA) [Member]
Royalty percentage			5%
Less than 500,000,000 [Member]
Royalty Rate		2%
Less than 500,000,000 [Member] | Subsequent Event [Member]
Royalty Rate				2%
From 500,000,000 to less than 1,000,000,000 [Member]
Royalty Rate		4%
From 500,000,000 to less than 1,000,000,000 [Member] | Subsequent Event [Member]
Royalty Rate				4%
Greater than 1,000,000,000 [Member]
Royalty Rate		6%
Greater than 1,000,000,000 [Member] | Subsequent Event [Member]
Royalty Rate				6%
Board Of Directors [Member] | Subsequent Event [Member] | Common Stock [Member]
Number of shares issued, shares	250,000
Number of shares issued	$ 500,000
License Agreement [Member] | Forte Animal Health, Inc. [Member]
Non-refundable milestone payments		$ 100,000
Royalty term		15 years
Forte Animal Health, Inc. [Member]
Number of shares issued			2,235,000
Equity method investment, ownership percentage			15%
Forte Animal Health, Inc. [Member] | Amended License Agreement [Member]
Notes payable					$ 1,775,275
Interest payable					264,790
Forte Animal Health, Inc. [Member] | Amended License Agreement [Member] | Other Vendor And Employee [Member]
Interest payable					$ 1,125,086

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

12 Months Ended

Nov. 01, 2022

Jul. 25, 2022

Jul. 18, 2022

Jul. 15, 2022

Apr. 29, 2020

Mar. 31, 2022

Mar. 31, 2022

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Mar. 24, 2023

Jul. 19, 2022

Jul. 05, 2022

Related Party Transaction [Line Items]

Debt Instrument face amount

$ 100,000

Debt instrument description

The third note is for the principal amount of $200,000. Each of the three notes: (a) matures on July 19, 2023, with the Company having the option to extend the maturity date by six months (b) carries a six percent (6.00%) per annum simple interest rate; (c) provides that, if converted by the holder in accordance with its terms, the Company shall issue a number of shares of common stock in the Company to the holder of the note equal to (i) the principal amount of the note divided by (ii) $0.05, subject to certain equitable adjustments; and (d) requires the note holder to notify the Company in writing by 11:59 p.m. on July 22, 2022, the expiration of the conversion provision in each note; of its intent to exercise its conversion right. If converted into shares of common stock, each of the three notes prohibits the note holder, without the prior written consent of the Company, from selling, pledging, or otherwise transferring such shares for one year from their date of issuance, except that up to 5% of the shares may be sold, pledged, or otherwise transferred during three of every four calendar quarters during the 18-month period following the issuance date of the converted Note

Debt instrument face amount

$ 200,000

Debt instrument maturity date

Jul. 19, 2023

Interest rate

6%

Share price

$ 0.05

Number of shares convertible shares

$ 200,000

Number of shares convertible shares

2,500,000

Non convertible note

$ 100,000

Common stock, par value

$ 0.0001

$ 0.0001

Convertible price

$ 6,283,168

$ 56,480

Promissory Note [Member]

Related Party Transaction [Line Items]

Notes payable

$ 200,000

Convertible price

$ 0.05

Settlement Agreement [Member] | Promissory Note [Member]

Related Party Transaction [Line Items]

Convertible price

6

MSWilson [Member]

Related Party Transaction [Line Items]

Related party transaction description of transaction

(a) 25% below any current offering price (or the most recent offering price if the Company is not engaged in the offering) or (b) 50% below the Company’s current common stock value as determined by the average of the previous 30 days’ closing market prices

Wages

$ 313,164

Reimbursable expenses

52,578

MRFarmer [Member]

Related Party Transaction [Line Items]

Related party transaction description of transaction

(a) 25% below any current offering price (or the most recent offering price if the Company is not engaged in the offering) or (b) 50% below the Company’s current common stock value as determined by the average of the previous 30 days’ closing market prices

MRPhelps [Member]

Related Party Transaction [Line Items]

Related party transaction description of transaction

Mr. Phelps was also eligible to receive a salary increase of 20% for his second year of employment and a salary increase of 15% for his third year of employment. Mr. Phelps also had the opportunity to receive a discretionary bonus of up to 33% based on the achieved milestones and goals

Convertible debt

$ 400,000

Robert Wilson [Member]

Related Party Transaction [Line Items]

Wages

365,742

Ms.Griffin [Member]

Related Party Transaction [Line Items]

Wages

1,231,787

Mr.Wilson [Member]

Related Party Transaction [Line Items]

Wages

230,000

Employee owed amount

$ 1,827,530

Chief Executive Officer [Member] | MSWilson [Member]

Related Party Transaction [Line Items]

Monthly fee expenses

$ 21,000

Insurance paid expenses

2,800

Chief Financial Officer [Member] | MRFarmer [Member]

Related Party Transaction [Line Items]

Consulting fees expenses

10,500

Chief Financial Officer [Member] | Mr. Farmer [Member]

Related Party Transaction [Line Items]

Consulting fees expenses

$ 2,800

MRPhelps [Member] | Employment agreement [Member]

Related Party Transaction [Line Items]

Employee benefit

$ 240,000

MSWilson [Member] | Settlement Agreement [Member]

Related Party Transaction [Line Items]

Employee benefit owed

$ 1,211,366

Common stock, par value

$ 0.05

Murphy [Member] | Settlement Agreement [Member]

Related Party Transaction [Line Items]

Common stock conversion description

On July 25, 2022, Murphy Advisors converted the Murphy Note into 24,227,320 shares of common stock, of which Murphy Advisors received 15,604,818 shares, Pixelheads, Inc., of whose shares Mr. Wilson is the sole beneficial owner, received 3,695,358 shares, and Global Reverb Corporation, of whose shares Ms. Griffin is the sole beneficial owner, received the remaining 4,927,144 shares. All shares issued as a result of converting the Murphy Note are required to be restricted from transfer for 12 months following the date of issuance, then subject to a lock-up leak of 5% per quarter for three out of four quarters for the following 18 months

Dr.Moore [Member] | Settlement Agreement [Member]

Related Party Transaction [Line Items]

Compensation expense

$ 230,250

Accrued expense

15,000

$ 15,000

Officer [Member] | Settlement Agreement [Member]

Related Party Transaction [Line Items]

Debt instrument face amount

$ 230,250

$ 230,250

Interest rate

6%

6%

Compensation expense

$ 60,000

120,000

Consulting service

95,250

Convertible of common shares

4,605,000

Director [Member] | Settlement Agreement [Member]

Related Party Transaction [Line Items]

Convertible price

$ 135,000

Dr.Selsky [Member] | Settlement Agreement [Member]

Related Party Transaction [Line Items]

Debt instrument face amount

$ 125,000

$ 125,000

Interest rate

6%

6%

Compensation expense

$ 250,000

$ 35,000

Accrued expense

$ 15,000

$ 15,000

Convertible of common shares

2,500,000

Compensation accrued expense

$ 50,000

Mr.Salomonsky [Member] | Settlement Agreement [Member]

Related Party Transaction [Line Items]

Convertible price

$ 125,000

Convertible of common shares

2,500,000

H.Louis Salomonsky [Member] | Promissory Notes [Member]

Related Party Transaction [Line Items]

Interest rate

8%

Notes payable

$ 100,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 24, 2023	Jan. 19, 2023	Jan. 10, 2023	Dec. 31, 2022
Subsequent Event [Line Items]
Debt Instrument, Face Amount				$ 200,000
Interest rate				6%
Promissory Notes [Member] | H.Louis Salomonsky [Member]
Subsequent Event [Line Items]
Interest rate	8%
Subsequent Event [Member] | Promissory Notes [Member] | H.Louis Salomonsky [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 100,000
Maturity date description	mature in 90 days
Interest rate	8%
Subsequent Event [Member] | Majority Shareholders [Member]
Subsequent Event [Line Items]
Ownership percentage			50.83%
Subsequent Event [Member] | Majority Shareholder [Member]
Subsequent Event [Line Items]
Share held by related party			42,225,908
Subsequent Event [Member] | TaiwanJ Pharmaceuticals. Inc. [Member]
Subsequent Event [Line Items]
Stock issued during period, shares		250,000
Subsequent Event [Member] | Three Lenders [Member] | Promissory Notes [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 150,000